David van Sickle Speaker Interview - GreyGreen | A Global ... · Disease Control and Prevention,...
1
align in where they expect digital solutions to be put to work. Some digital companies channel them toward challenging individual clinical cases, while others aim to shift the overall population distribution. This can have wide-ranging influences on product and service design, recruitment, enrolment, and ongoing support…not to mention payment models! What are you most looking forward to at the Digital Therapeutics & Digital Medicine Summit? This is an emerging industry with enormous potential to improve medical outcomes. The sector contains a group of thoughtful people who are obsessed with the promising yet puzzling future of healthcare. We are building businesses that by definition are trying to create surplus value for society. At the summit there will be a great mix of leaders from digital companies, pharma, biotech’s, investors and healthcare systems. I am looking forward to sharing with this group, learning from peers and creating new connections that can lead to future collaborations. David Van Sickle CEO & Co-Founder Industry Expert Interview: David Van Sickle is CEO and Co-Founder of Propeller Health. David was formerly an Epidemic Intelligence Service Officer with the Centers for Disease Control and Prevention, and a Robert Wood Johnson Foundation Health and Society Scholar at the University of Wisconsin School of Medicine and Public Health. He also writes about asthma epidemiology, medical anthropology, and global chronic respiratory disease. Why are digital therapeutics and digital medicine getting a lot of attention right now? A variety of effective treatments have accumulated, relatively unused, in many therapeutic areas. Digital approaches have recently drawn a lot of attention because they can help put existing treatments to better and more productive use. Increasingly, digital approaches use computing power to personalize therapy, adapt dosing, and encourage more appropriate and effective management of diseases. In a mechanical-sense, they can also make therapies better-suited to the routines of daily life by increasing their utility and maximizing their benefit, while minimizing their disruption. This means widespread changes to the experience of a chronic disease through making care and treatment more personal, timely, convenient, affordable and accessible. What should pharma’s role be in this ecosystem? We believe pharmaceutical companies can use digital tools to build better relationships with the people and physicians who use their medicines, and create more holistic, supportive and beneficial therapeutic offerings. Therefore, digital companions become the physical manifestation of a set of services embedded with the years of accumulated knowledge, learning, and testing that characterize these companies. In the respiratory disease space, a lot of activity is surrounding the practical development of drug-digital pairings. These range from simple reminders to technology-driven improvements in drug delivery, but their goal is the same: to improve outcomes for people with asthma and COPD by ensuring that the people who are prescribed these medications actually benefit from using them. Digital health companies working with pharma also have to remember that these are global businesses. So the orientations of payers and providers to digital products in foreign markets can be as important as they are different from those in the U.S. How should digital therapeutic and digital medicine companies interact with payers and providers? One of the least appreciated challenges is how to productively reconcile differing views of the eligible population. Payer, provider and pharmaceutical organizations rarely David will be showcasing the exciting work at Propeller Health at the Digital Therapeutics & Digital Medicine Summit 2018 on Feb 27 th -28 th in San Jose, CA. His presentation is titled “Digital Medicines and the Personal Future Care and Treatment for Chronic Respiratory Disease Digital Therapeutics & Digital Medicine Summit 2018 Feb 27 th -28 th , San Jose, CA Pioneers Perspectives www.digitaltxsummit.com
Transcript of David van Sickle Speaker Interview - GreyGreen | A Global ... · Disease Control and Prevention,...
aligninwheretheyexpectdigitalsolutionstobeputtowork.Somedigitalcompanieschannelthemtowardchallengingindividualclinicalcases,whileothersaimtoshifttheoverallpopulationdistribution.Thiscanhavewide-ranginginfluencesonproductandservicedesign,recruitment,enrolment,andongoingsupport…nottomentionpaymentmodels!
WhatareyoumostlookingforwardtoattheDigitalTherapeutics&DigitalMedicineSummit?Thisisanemergingindustrywithenormouspotentialtoimprovemedicaloutcomes.Thesectorcontainsagroupofthoughtfulpeoplewhoareobsessedwiththepromisingyetpuzzlingfutureofhealthcare.Wearebuildingbusinessesthatbydefinitionaretryingtocreatesurplusvalueforsociety.Atthesummittherewillbeagreatmixofleadersfromdigitalcompanies,pharma,biotech’s,investorsandhealthcaresystems.Iamlookingforwardtosharingwiththisgroup,learningfrompeersandcreatingnewconnectionsthatcanleadtofuturecollaborations.
DavidVanSickleCEO&Co-Founder
IndustryExpertInterview:
DavidVanSickleisCEOandCo-FounderofPropellerHealth.DavidwasformerlyanEpidemicIntelligenceServiceOfficerwiththeCenters forDiseaseControlandPrevention,andaRobertWoodJohnsonFoundationHealthandSocietyScholarattheUniversityofWisconsinSchoolofMedicineandPublicHealth.Healsowritesaboutasthmaepidemiology,medicalanthropology,andglobalchronicrespiratorydisease.
Whyaredigitaltherapeuticsanddigitalmedicinegettingalotofattentionrightnow?Avarietyofeffectivetreatmentshaveaccumulated,relativelyunused,inmanytherapeuticareas.Digitalapproacheshaverecentlydrawnalotofattentionbecausetheycanhelpputexistingtreatmentstobetterandmoreproductiveuse.Increasingly,digitalapproachesusecomputingpowertopersonalizetherapy,adaptdosing,andencouragemoreappropriateandeffectivemanagementofdiseases.Inamechanical-sense,theycanalsomaketherapiesbetter-suitedtotheroutinesofdailylifebyincreasingtheirutilityandmaximizingtheirbenefit,whileminimizingtheirdisruption.Thismeanswidespreadchangestotheexperienceofachronicdiseasethroughmakingcareandtreatmentmorepersonal,timely,convenient,affordableandaccessible.
Whatshouldpharma’srolebeinthisecosystem?Webelievepharmaceuticalcompaniescanusedigitaltoolstobuildbetterrelationshipswiththepeopleandphysicianswhousetheirmedicines,andcreatemoreholistic,supportiveandbeneficialtherapeuticofferings.Therefore,digitalcompanionsbecomethephysicalmanifestationofasetofservicesembeddedwiththeyearsofaccumulatedknowledge,learning,andtestingthatcharacterizethesecompanies.
Intherespiratorydiseasespace,alotofactivityissurroundingthepracticaldevelopmentofdrug-digitalpairings.Theserangefromsimplereminderstotechnology-drivenimprovementsindrugdelivery,buttheirgoalisthesame:toimproveoutcomesforpeoplewithasthmaandCOPDbyensuringthatthepeoplewhoareprescribedthesemedicationsactuallybenefitfromusingthem.
Digitalhealthcompaniesworkingwithpharmaalsohavetorememberthattheseareglobalbusinesses.SotheorientationsofpayersandproviderstodigitalproductsinforeignmarketscanbeasimportantastheyaredifferentfromthoseintheU.S.
Howshoulddigitaltherapeuticanddigitalmedicinecompaniesinteractwithpayersandproviders?Oneoftheleastappreciatedchallengesishowtoproductivelyreconciledifferingviewsoftheeligiblepopulation.Payer,providerandpharmaceuticalorganizationsrarely
DavidwillbeshowcasingtheexcitingworkatPropellerHealthattheDigitalTherapeutics&DigitalMedicineSummit2018onFeb27th-28th inSanJose,CA.Hispresentationistitled“DigitalMedicinesandthePersonalFutureCareandTreatmentforChronicRespiratoryDisease
Digital Therapeutics &Digital Medicine Summit 2018 Feb 27th-28th, San Jose, CA
Pioneers Perspectives
www.digitaltxsummit.com
